The Anti-Malarial Drug Artesunate Attenuates Cardiac Injury in a Rodent Model of Myocardial Infarction.

Détails

ID Serval
serval:BIB_5C59BA71F335
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
The Anti-Malarial Drug Artesunate Attenuates Cardiac Injury in a Rodent Model of Myocardial Infarction.
Périodique
Shock
Auteur(s)
Khan A.I., Kapoor A., Che J., Martin L., Rogazzo M., Mercier T., Decosterd L., Collino M., Thiemermann C.
ISSN
1540-0514 (Electronic)
ISSN-L
1073-2322
Statut éditorial
In Press
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Résumé
Ischaemic heart disease remains the leading cause of morbidity and mortality in the Western world. Artesunate is the WHO-recommended drug of choice for complicated malaria (with organ failure). The administration of high doses of artesunate is safe in healthy volunteers (up to 8 mg/kg i.v) and patients with severe malaria (2.4 mg/kg i.v). We investigated the effects of artesunate (1 mg/kg) or its active metabolite dihydroartemisinin (DHA; 0.1 mg/kg) in a model of transient myocardial ischaemia/reperfusion (I/R) and evaluated the mechanism of action of the observed cardioprotective effects of artesunate and DHA. We report here for the first time that the administration of artesunate at the onset of reperfusion attenuates the myocardial injury associated with I/R. The observed beneficial effects of artesunate are associated with i) activation of the PI3K/Akt/ERK 1/2 (RISK) pathway, ii) activation of eNOS, iii) inhibition of GSK-3β, iv) inhibition of NF-κB, and v) activation of the STAT3 (SAFE) pathway. In conclusion, as artesunate has an excellent safety profile, the above data should stimulate clinical trials in patients with acute coronary syndromes.

Pubmed
Création de la notice
07/09/2017 7:42
Dernière modification de la notice
27/08/2019 5:26
Données d'usage